Table 1.
Baseline patient characteristics.
| Early-Stage NSCLC (Stages I–IIIA) |
Advanced-Stage NSCLC (Stages IIIB–IV) |
p-Value | |
|---|---|---|---|
| N (%) | N (%) | ||
| No. of patients | 723 (46.6%) | 827 (53.4%) | |
| Age | |||
| ≤60 years | 157 (21.7%) | 180 (21.8%) | 1 |
| >60 years | 566 (78.3%) | 647 (78.2%) | 1 |
| Gender | |||
| Men | 353 (48.8%) | 445 (53.8%) | 0.0564 |
| Women | 370 (51.2%) | 382 (46.2%) | 0.0564 |
| Histological NSCLC subtypes | |||
| Adenocarcinoma | 567 (78.4%) | 650 (78.6%) | 0.9830 |
| Squamous Cell Carcinoma | 87 (12%) | 106 (12.8%) | 0.6970 |
| Adenosquamous Carcinoma | 15 (2.1%) | 13 (1.6%) | 0.5822 |
| Sarcomatoid Carcinoma | 19 (2.6%) | 22 (2.7%) | 1 |
| Large Cell Carcinoma | 14 (1.9%) | 2 (0.2%) | 0.0015 |
| Large Cell Neuroendocrine Carcinoma | 11 (1.5%) | 8 (1%) | 0.4487 |
| Other NSCLC subtypes | 1 (0.1%) | 4 (0.5%) | 0.3798 |
| NSCLC not otherwise specified (NOS) | 9 (1.2%) | 22 (2.7%) | 0.0713 |
| Stage according to UICC (8th edition) | |||
| IA1 | 43 (2.8%) | ||
| IA2 | 126 (8.1 %) | ||
| IA3 | 73 (4.7%) | ||
| IB | 89 (5.7%) | ||
| IIA | 36 (2.3%) | ||
| IIB | 135 (8.7%) | ||
| IIIA | 221 (14.3%) | ||
| IIIB | 134 (8.6%) | ||
| IIIC | 37 (2.4%) | ||
| IVA | 246 (15.9%) | ||
| IVB | 410 (26.5%) | ||
| WHO-Grading as available N (%) | 605 (83.7%) | 534 (64.6%) | |
| G1 | 7 (1.2%) | 1 (0.2%) | 0.0736 |
| G2 | 325 (53.7%) | 131 (24.5%) | <0.001 |
| G3 | 250 (41.3%) | 378 (70.8%) | <0.001 |
| G4 | 23 (3.8%) | 24 (4.5%) | 0.6619 |
| Smoker status as available N (%) | 432 (59.8%) | 540 (65.3%) | |
| Never smoker | 14 (3.2%) | 30 (5.6%) | 0.1165 |
| Former smoker | 162 (37.5%) | 196 (36.3%) | 0.7492 |
| Current smoker | 256 (59.3%) | 314 (58.1%) | 0.7764 |